Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission

PLoS One. 2015 Mar 16;10(3):e0119595. doi: 10.1371/journal.pone.0119595. eCollection 2015.

Abstract

Persistent complete donor chimerism is an important clinical indicator for remissions of hematological malignancies after HLA-matched allogeneic stem cell transplantation (SCT). However, the mechanisms mediating the persistence of complete donor chimerism are poorly understood. The frequent coincidence of complete donor chimerism with graft-versus-leukemia effects and graft-versus-host disease suggests that immune responses against minor histocompatibility antigens (mHags) are playing an important role in suppressing the host hematopoiesis after allogeneic SCT. Here, we investigated a possible relationship between donor immune responses against the hematopoiesis-restricted mHag HA-1 and the long-term kinetics of host hematopoietic chimerism in a cohort of 10 patients after allogeneic HLA-matched, HA-1 mismatched SCT. Functional HA-1 specific CTLs (HA-1 CTLs) were detectable in 6/10 patients lysing host-type hematopoietic cells in vitro. Presence of HA-1 CTLs in the peripheral blood coincided with low host hematopoiesis levels quantified by highly sensitive mHag specific PCR. Additionally, co-incubation of host type CD34+ cells with HA-1 CTLs isolated after allogeneic SCT prevented progenitor and cobblestone area forming cell growth in vitro and human hematopoietic engraftment in immunodeficient mice. Conversely, absence or loss of HA-1 CTLs mostly coincided with high host hematopoiesis levels and/or relapse. In summary, in this first study, presence of HA-1 CTLs paralleled low host hematopoiesis levels. This coincidence might be supported by the capacity of HA-1 CTLs isolated after allogeneic SCT to specifically eliminate host type hematopoietic stem/progenitor cells. Additional studies involving multiple mismatched mHags in more patients are required to confirm this novel characteristic of mHag CTLs as factor for the persistence of complete donor chimerism and leukemia remission after allogeneic SCT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AC133 Antigen
  • Antigens, CD / metabolism
  • Antigens, CD34 / metabolism
  • Glycoproteins / metabolism
  • Graft vs Leukemia Effect
  • Humans
  • Leukemia / genetics
  • Leukemia / immunology*
  • Leukemia / therapy*
  • Minor Histocompatibility Antigens / genetics
  • Minor Histocompatibility Antigens / metabolism*
  • Oligopeptides / genetics
  • Oligopeptides / metabolism*
  • Peptides / metabolism
  • Stem Cell Transplantation
  • T-Lymphocytes, Cytotoxic / metabolism
  • Transplantation, Homologous

Substances

  • AC133 Antigen
  • Antigens, CD
  • Antigens, CD34
  • Glycoproteins
  • HA-1 antigen
  • Minor Histocompatibility Antigens
  • Oligopeptides
  • Peptides

Grants and funding

This work is supported in part by funding from: Sander foundation (Munich, Germany, project code 2005.111.1); [http://www.wilhelm-sander-stiftung.de/]; the Integrated Research and Treatment Center Transplantation (IFB-Tx) funded by the German Federal Ministry of Education and Research (reference number: 01EO0802 and 01EO1302); [http://www.ifb-tx.de/]; the Dutch Cancer Society (Koningin Wilhelmina Fonds, Amsterdam, The Netherlands, project code UL2006-3482); [http://www.kwf.nl/]; the Netherlands Organization for Scientific Research (NWO; Den Haag, The Netherlands); [http://www.nwo.nl/]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.